Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (2): 247-252    DOI: 10.12892/ejgo4031.2018
Original Research Previous articles | Next articles
An experimental study of cyclinD1 expression in human epithelial ovarian cancer cells
Jun Dai1, *(), Peishu Liu1, Yangyun Liu2, Wei Cai3
1 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China
2 Department of Otolaryngology, The 163th Hospital of PLA, Changsha, China
3 Department of Orthopaedics, The 163th Hospital of PLA, Changsha, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of investigation: As an important oncogene, cyclinD1 has close relationship with carcinomars. This study aims to investigate the correlation between cyclinD1 expression and ovarian cancer cell growth capability and apoptosis. Materials and Methods: Epithelial ovarian cancer (EOC) cell line 3AO was cultured and incubated with different concentrations (0, 1, 5, and 10 ug/ml) of cisplatin. RT-PCR and FCM analysis were used to detect cyclinD1 mRNA and protein expression, 3AO cell cycles, cell growth capability, and apoptosis were assessed by FCM. Results: EOC cell 3AO presented anti-apoptosis capabilities and cyclinD1 overexpression. After treatment with cisplatin, low cyclinD1 expression, decelerated cell growth capability, and high cell apoptosis levels were detected. Conclusion: CyclinD1 expression has closely correlated with EOC cell growth and apoptosis. CyclinD1 may be a good biomarker for monitoring the progress of EOC.
Key words:  Epithelial ovarian cancer      CyclinD1      RT- PCR      Flow cytometry     
Published:  10 April 2018     
*Corresponding Author(s):  JUN DAI     E-mail:  pl_sci@163.com

Cite this article: 

Jun Dai, Peishu Liu, Yangyun Liu, Wei Cai. An experimental study of cyclinD1 expression in human epithelial ovarian cancer cells. European Journal of Gynaecological Oncology, 2018, 39(2): 247-252.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4031.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I2/247

[1] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[2] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[3] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[4] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[5] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[6] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma – case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[7] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[8] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[9] Li-Yuan Guo, San-Yuan Zhang, Chen Chen, Hao-Xia Zeng, Feng-Yan Li, Qiu-Xiang Xu. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 615-620.
[10] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[11] B.D. de-la-Noval, M.D. Diestro Tejeda, L. Yébenes, I. Zapardiel, A. Hernández Gutiérrez, J. De-Santiago García. Recurrent endometriosis following tibolone hormone replacement therapy after mucinous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 310-313.
[12] J.M. Mañé, B. Calvo, U. Aresti, S. Carrera, A. Sancho, E. Azkona, I. Marrodán, I. Ugalde, I. Rubio, G. López-Vivanco. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: what is our clinical practice?[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 695-699.
[13] F. Celik, M. Kose. Increased neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can be used to distinguish ovarian masses[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 720-723.
[14] A. Stiekema, C.A.R. Lok, M. v Beurden, S.B. Coffelt, W.J. van Driel, G.G. Kenter, C.M. Korse. Serial measurements of serum human epididymal protein 4 in patients at risk for ovarian cancer[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 750-755.
[15] A. Bastani, A. Asghary, M.H. Heidari, F. Karimi-Busheri. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 418-424.
No Suggested Reading articles found!